224:
29:
490:
Manitpisitkul P, Shalayda K, Russell L, Sanga P, Solanki B, Caruso J, et al. (September 2018). "Pharmacokinetics and Safety of
Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study".
437:
Manitpisitkul P, Shalayda K, Russell L, Sanga P, Williams Y, Solanki B, et al. (September 2018). "Bioavailability and
Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies".
300:
555:
402:
in healthy volunteers in approximately 14 days. It has a relatively long half life between 68 and 101 hours in
Japanese subjects and between 82 and 130 hours in Caucasian subjects.
314:
342:
InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+
405:
Mavatrep is largely eliminated non-renally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.
414:
369:
334:
57:
540:
163:
550:
203:
192:
219:
545:
78:
516:
463:
508:
455:
152:
500:
447:
240:
87:
172:
223:
387:
534:
112:
520:
467:
399:
377:
383:
Phase I trials have been completed in healthy
Japanese and Caucasian volunteers.
276:
143:
512:
459:
123:
20:
132:
98:
504:
451:
183:
28:
390:
include thermohypoesthesia, chills, feeling cold, and feeling hot.
365:
322:
CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O
299:
290:
373:
208:
398:
When administered orally once a day, mavatrep reached
368:
receptor selective competitive antagonist. It is an
288:
275:
239:
234:
202:
182:
162:
142:
122:
97:
77:
48:
40:
35:
111:
556:Transient receptor potential channel modulators
86:
8:
19:
222:
151:
27:
493:Clinical Pharmacology in Drug Development
440:Clinical Pharmacology in Drug Development
171:
426:
339:
319:
218:
131:
62:
372:that may be a potential treatment for
18:
191:
69:-benzimidazol-5-yl]phenyl]propan-2-ol
7:
485:
483:
481:
479:
477:
432:
430:
102:
415:List of investigational analgesics
14:
263:
257:
251:
347:Key:ORDHXXHTBUZRCN-NTEUORMPSA-N
269:
245:
16:Investigational analgesic drug
1:
572:
235:Chemical and physical data
370:investigational analgesic
330:
310:
53:
26:
541:Ion channel blockers
23:
551:Experimental drugs
386:Potential common
355:
354:
301:Interactive image
204:CompTox Dashboard
563:
525:
524:
505:10.1002/cpdd.413
487:
472:
471:
452:10.1002/cpdd.412
434:
394:Pharmacokinetics
303:
283:
271:
265:
259:
253:
247:
227:
226:
212:
210:
195:
175:
155:
135:
115:
105:
104:
90:
31:
24:
22:
571:
570:
566:
565:
564:
562:
561:
560:
531:
530:
529:
528:
489:
488:
475:
436:
435:
428:
423:
411:
396:
388:adverse effects
351:
348:
343:
338:
337:
326:
323:
318:
317:
306:
281:
268:
262:
256:
250:
230:
206:
198:
178:
158:
138:
118:
101:
93:
73:
70:
61:
60:
17:
12:
11:
5:
569:
567:
559:
558:
553:
548:
543:
533:
532:
527:
526:
499:(7): 712–726.
473:
446:(7): 699–711.
425:
424:
422:
419:
418:
417:
410:
407:
395:
392:
353:
352:
350:
349:
346:
344:
341:
333:
332:
331:
328:
327:
325:
324:
321:
313:
312:
311:
308:
307:
305:
304:
296:
294:
286:
285:
279:
273:
272:
266:
260:
254:
248:
243:
237:
236:
232:
231:
229:
228:
220:DTXSID90241905
215:
213:
200:
199:
197:
196:
188:
186:
180:
179:
177:
176:
168:
166:
160:
159:
157:
156:
148:
146:
140:
139:
137:
136:
128:
126:
120:
119:
117:
116:
108:
106:
95:
94:
92:
91:
83:
81:
75:
74:
72:
71:
64:
56:
55:
54:
51:
50:
46:
45:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
568:
557:
554:
552:
549:
547:
544:
542:
539:
538:
536:
522:
518:
514:
510:
506:
502:
498:
494:
486:
484:
482:
480:
478:
474:
469:
465:
461:
457:
453:
449:
445:
441:
433:
431:
427:
420:
416:
413:
412:
408:
406:
403:
401:
393:
391:
389:
384:
381:
379:
375:
371:
367:
363:
359:
345:
340:
336:
329:
320:
316:
309:
302:
298:
297:
295:
292:
287:
280:
278:
274:
244:
242:
238:
233:
225:
221:
217:
216:
214:
205:
201:
194:
193:ChEMBL2364618
190:
189:
187:
185:
181:
174:
170:
169:
167:
165:
161:
154:
150:
149:
147:
145:
141:
134:
130:
129:
127:
125:
121:
114:
110:
109:
107:
100:
96:
89:
85:
84:
82:
80:
76:
68:
63:
59:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
496:
492:
443:
439:
404:
400:steady-state
397:
385:
382:
378:inflammation
362:JNJ‐39439335
361:
357:
356:
66:
65:2-ethenyl]-3
44:JNJ-39439335
284: g·mol
88:956274-94-5
49:Identifiers
41:Other names
546:Analgesics
535:Categories
421:References
289:3D model (
277:Molar mass
173:F197218T99
144:ChemSpider
79:CAS Number
58:IUPAC name
521:11755963
513:29125703
468:32666782
460:29125700
409:See also
358:Mavatrep
153:29271895
124:DrugBank
113:17751090
21:Mavatrep
376:and/or
364:) is a
282:422.451
241:Formula
133:DB12875
99:PubChem
519:
511:
466:
458:
315:SMILES
184:ChEMBL
517:S2CID
464:S2CID
366:TRPV1
335:InChI
291:JSmol
509:PMID
456:PMID
374:pain
164:UNII
501:doi
448:doi
209:EPA
103:CID
537::
515:.
507:.
495:.
476:^
462:.
454:.
442:.
429:^
380:.
255:21
249:25
523:.
503::
497:7
470:.
450::
444:7
360:(
293:)
270:O
267:2
264:N
261:3
258:F
252:H
246:C
211:)
207:(
67:H
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
